KIS induces proliferation and the cell cycle progression through the phosphorylation of p27Kip1 in leukemia cells

Related Experiment Video

Updated: Jul 6, 2026

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

Satoki Nakamura1, Keiji Okinaka, Isao Hirano

  • 1Department of Internal Medicine III, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan. satonaka@hama-med.ac.jp

Leukemia Research
|April 4, 2008
PubMed

Insights

Kinase interacting substrate (KIS) protein promotes leukemia cell cycle progression by phosphorylating p27(Kip1). Reducing KIS inhibits proliferation and induces G0/G1 arrest in leukemia cells, suggesting KIS as a therapeutic target.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Leukemia is characterized by uncontrolled cell proliferation.
  • The cell cycle regulatory protein p27(Kip1) plays a crucial role in cell cycle control.
  • The function of Kinase Interacting Substrate (KIS) in leukemia cell cycle regulation is not fully understood.

Purpose of the Study:

  • To investigate the role of KIS in leukemia cell proliferation and cell cycle progression.
  • To determine the interaction between KIS and p27(Kip1).
  • To assess KIS expression levels in primary leukemia specimens.

Main Methods:

  • Lentivirus-mediated siRNA was used to reduce KIS mRNA expression in CEM, MOLT4, and SUP-B15 leukemia cell lines.
  • Western blotting and co-immunoprecipitation were employed to analyze protein interactions and phosphorylation.
  • Cell proliferation assays and cell cycle analysis (G0/G1 fraction) were performed.
  • KIS mRNA and protein expression levels were quantified in primary leukemia samples (AML, MDS, ALL).

Main Results:

  • Reduction of KIS expression inhibited leukemia cell proliferation in a time-dependent manner.
  • KIS directly interacts with p27(Kip1) and its reduction inhibited S10 phosphorylation of p27(Kip1).
  • Inhibition of p27(Kip1) S10 phosphorylation led to increased G0/G1 cell cycle arrest.
  • KIS mRNA and protein were significantly upregulated in primary leukemia specimens (AML, MDS, ALL).

Conclusions:

  • KIS promotes leukemia cell cycle progression by phosphorylating p27(Kip1) at S10.
  • Elevated KIS levels in leukemia cells contribute to uncontrolled proliferation.
  • Targeting KIS may represent a potential therapeutic strategy for leukemia.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.